The safety and efficacy of monoclonal antibody therapy with low-dose bamlanivimab plus etesevimab was similar to that of higher doses of the drug combination in patients with mild to moderate COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback